Multiple Myeloma

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.

Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.

Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.

A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.

Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.

Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.

D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.

Belantamab mafodotin plus Pd improved PFS and response rates in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.

Talquetamab led to durable responses and promising survival outcomes in patients with relapsed/refractory multiple myeloma.

CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.

Elotuzumab plus PVd elicited responses in patients with relapsed/refractory multiple myeloma after a median of 3 prior lines of therapy.

Elena Maroto-Martin, PhD, highlights the mechanism of action and efficacy of MZB1 TCR-like CAR T-cell therapy in multiple myeloma.

Talquetamab plus teclistamab produced responses with a high rate of infections in relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of belantamab mafodotin (Blenrep) in adult patients with relapsed or refractory multiple myeloma.

The FDA’s ODAC voted in favor of the risk/benefit profile of subcutaneous daratumumab in high-risk smoldering multiple myeloma.

Thierry Facon, MD, details the rationale for evaluating Isa-VRd in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Elena Maroto-Martin, PhD, discusses early efficacy data with an MZB1-targeted TCR-like CAR T-cell therapy in multiple myeloma and Waldenström macroglobulinemia.

Armin Sobh, PhD, discusses the therapeutic potential of selectively targeting NSD2 in the treatment of multiple myeloma.

Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.

Elena Maroto-Martin, PhD, discusses the rationale for developing TCR-like CAR T-cell therapy in multiple myeloma and other hematologic malignancies.

Amin Sobh, PhD, discusses ongoing efforts to investigate the role of NSD2 expression in modulating immune surveillance in multiple myeloma.

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.